VALN vs. IMCR, NVAX, RXRX, NMRA, BCRX, VIR, SANA, AUTL, RLAY, and CGEM
Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Immunocore (IMCR), Novavax (NVAX), Recursion Pharmaceuticals (RXRX), Neumora Therapeutics (NMRA), BioCryst Pharmaceuticals (BCRX), Vir Biotechnology (VIR), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), and Cullinan Therapeutics (CGEM). These companies are all part of the "biological products, except diagnostic" industry.
Immunocore (NASDAQ:IMCR) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
In the previous week, Valneva had 12 more articles in the media than Immunocore. MarketBeat recorded 15 mentions for Valneva and 3 mentions for Immunocore. Valneva's average media sentiment score of 1.04 beat Immunocore's score of 0.54 indicating that Immunocore is being referred to more favorably in the media.
Valneva has a net margin of -15.88% compared to Valneva's net margin of -22.60%. Immunocore's return on equity of -14.56% beat Valneva's return on equity.
Immunocore currently has a consensus target price of $82.75, suggesting a potential upside of 106.20%. Valneva has a consensus target price of $21.67, suggesting a potential upside of 198.85%. Given Immunocore's stronger consensus rating and higher possible upside, analysts plainly believe Valneva is more favorable than Immunocore.
Immunocore received 27 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 72.97% of users gave Immunocore an outperform vote while only 56.25% of users gave Valneva an outperform vote.
Immunocore has higher revenue and earnings than Valneva. Immunocore is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.
Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500.
84.5% of Immunocore shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 9.1% of Immunocore shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Valneva beats Immunocore on 10 of the 18 factors compared between the two stocks.
Get Valneva News Delivered to You Automatically
Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
